Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
NCT03149809Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- Mar 2018
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of solifenacin in overactive bladder (OAB), sponsored by VA Office of Research & Development. Started Mar 2018; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03149809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149809.